Dr. Airriess has a long history of connecting business and science in the development of medtech and biotech solutions. As CEO of Cortechs.ai he drives strategic development of the company that pioneered the application of volumetric MRI to routine clinical practice. Over the past 12 years, Cortechs.ai’ flagship volumetric MRI product, NeuroQuant, has been the go-to application for fast, objective volumetric analysis of neurodegenerative conditions such as Alzheimer’s, multiple sclerosis, epilepsy, and traumatic brain injury.
Previously, as chief operating officer of California Stem Cell (acquired by Caladrius Biosciences), Dr. Airriess drove company development from start-up to the clinical development phase of several therapeutic candidates, including FDA approval to begin a Phase III clinical trial using autologous stem cells to treat metastatic melanoma.
Other positions held include assistant professor at the University of British Columbia, Canada, and director of scientific computing for the National Center for Microscopy and Imaging Research and the Biomedical Informatics Research Network, both headquartered at the University of California, San Diego. Dr. Airriess has a Ph.D. in cardiovascular physiology and was a post-doctoral fellow at the University of Cambridge, UK and the University of Sydney, Australia.